News

The July 2023 cardiology month in review features a Class I recall from the FDA, the latest recommendation statement from the USPSTF, and an update on 3 agents in the pipeline.

This recent research indicates the necessity for clinicians to be aware of the higher autoimmune disease susceptibility of those with previous rotavirus-associated hospitalization.

This endocrine case report feature a woman with a history of diabetes, hypertension, and marijuana use in her mid 50s brought to the ED for confusion by her friend and neighbor who states that she has been like this for 3 days. Can you determine how best to proceed?

Global estimate prevalence data suggest the virus affects more than 3% of the population, with available treatment and vaccination strategies used too infrequently.

In this interview with Dr. Gold, she describes her team’s recent findings from a phase 4 head-to-head study on risankizumab for psoriasis patients.

A protein targeted by some marketed lipid-lowering agents may increase risk of developing irritable bowel disease.

During the early pandemic period, video telehealth use increased among all veteran groups but differences were observed among American Indian/Alaska Native veterans.

Dr. Mikkael Sekeres discusses the approval of quizartinib (Vanflyta) and how it impacts the treatment of acute myeloid leukemia.

This new research suggests a potential need for policymakers to examine nursing home regulations related to staffing and to collaborate with administrators to create better policies.

The first known dose-effect relationship study between colorectal neoplasia and smoking in patients with IBD strengthens the importance of achieving cessation.

In this recent analysis of hyperhidrosis burden on patients, prevalence of the condition and its impacts on patients demonstrate the value of exploring knowledge gaps for this disease.

Our July 2023 endocrinology month in review features an FDA approval, topline results from a pair of major trials, and a pair of new guidelines related to the management and diagnosis of diabetes.

Presented at ASRS 2023, an analysis of the Portal trial suggests the efficacy and safety of PDS with ranibizumab was maintained over 5 years in patients with nAMD.

Many patients present to rheumatologists with arthralgia months or years before they are diagnosed with rheumatoid arthritis. Test your knowledge on progression of arthralgia to rheumatoid arthritis with this quiz.

Reports of a half-dozen confirmed cases of the rare vision-threatening condition has spurred conversation around the first-in-class geographic atrophy drug.

Presented at ASRS 2023, results suggest the potential proof-of-concept for the safety, tolerability, and efficacy of UBX1325 in patients with DME.

This approval is the first for an FLT3 inhibitor and it's specifically indicated for patients who have FLT3-ITD.

Dr. Hahn discusses an anchored matching-adjusted indirect comparison in patients with geographic atrophy, suggesting a greater reduction in observed lesion growth with monthly pegcetacoplan versus avacincaptad pegol.

This analysis of Medicare beneficiaries over age 71 suggests the importance of discrete severity measures of hearing loss in older adults, as opposed to binary hearing loss terminology.

New cross-sectional data show the sex gap in alcohol-related mortality has been narrowing since 1999, as women have become more susceptible to alcohol use and related diseases.

This cardiology case report from Brady Pregerson, MD, features a patient in their late 60s presenting with multiple episodes of chest pain. Check out the ECG and determine the correct diagnosis!

This interview segment with Dr. Kidon featured a discussion about her views on current research in the immunotherapy and food allergy space, as well as her views on the future.

An analysis of 7 international, longitudinal studies with nearly 20,000 patients details apparent increases in risk associated with daily alcohol consumption among healthy adults.

Presented at ASRS 2023, pegcetacoplan injection showed increasing treatment effects over 30 months for patients with geographic atrophy, with a consistent safety profile to previous phase 3 data.

Late-breaking findings at ASRS 2023 suggest daily home OCT imaging is sufficient for remotely monitoring fluid among patients with treatment-naïve nAMD.

Presented at ASRS 2023, the results showed clinically meaningful reductions in anti-VEGF treatment burden at all dose levels of intravitreal 4D-150 in patients with a high anti-VEGF need.

At ASRS 2023, results from the MOSAIC study indicate the substantial burden of geographic atrophy on patients and their caregivers across the United States and Canada.

Presented at ASRS 2023, study data suggest aflibercept 8 mg provided greater therapeutic benefit, an extended injection interval, and equivalent safety versus aflibercept 2 mg in eyes with nAMD.